Comparative efficacy of commercial infectious bursal disease vaccination strategies against emerging novel variant IBDV (Genotype A2d).
- DOI
- 10.1016/j.cimid.2026.102501
- Published
- 2026 Sep
- Container
- Comparative immunology, microbiology and infectious diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.cimid.2026.102501,
title = {Comparative efficacy of commercial infectious bursal disease vaccination strategies against emerging novel variant IBDV (Genotype A2d).},
author = {Issa KSAM and Ellakany HF and Gado AR and Elrayes SH and Abughanima II and Elbestawy AR and El Naggar RF and Salaheldin AH and Abdelsabour MA and Abd El-Hamid HS and Rohaim MA},
year = {2026},
journal = {Comparative immunology, microbiology and infectious diseases},
doi = {10.1016/j.cimid.2026.102501},
url = {https://doi.org/10.1016/j.cimid.2026.102501}
}RIS
TY - JOUR TI - Comparative efficacy of commercial infectious bursal disease vaccination strategies against emerging novel variant IBDV (Genotype A2d). AU - Issa KSAM AU - Ellakany HF AU - Gado AR AU - Elrayes SH AU - Abughanima II AU - Elbestawy AR AU - El Naggar RF AU - Salaheldin AH AU - Abdelsabour MA AU - Abd El-Hamid HS AU - Rohaim MA PY - 2026 JO - Comparative immunology, microbiology and infectious diseases DO - 10.1016/j.cimid.2026.102501 UR - https://doi.org/10.1016/j.cimid.2026.102501 ER -
APA
KSAM, I., HF, E., AR, G., SH, E., II, A., AR, E., RF, E. N., AH, S., MA, A., HS, A. E., & MA, R. (2026). Comparative efficacy of commercial infectious bursal disease vaccination strategies against emerging novel variant IBDV (Genotype A2d).. Comparative immunology, microbiology and infectious diseases. https://doi.org/10.1016/j.cimid.2026.102501
Source records
- pubmed · retrieved 2026-09-26T23:35:13.565Z